Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Enoxawel 40
Enoxawel 40 (Enoxaparin Injection 40 mg) is a low molecular weight heparin (LMWH) designed to prevent blood clot formation in high-risk patients undergoing surgery or prolonged immobilization.
Uses of Enoxawel 40
Prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
Prophylaxis in surgical patients (orthopedic, abdominal, general surgeries)
Clot prevention in bedridden patients with acute medical conditions
Benefits of Enoxawel 40
Reduces the risk of life-threatening blood clots
Predictable anticoagulant effect with minimal monitoring
Convenient subcutaneous administration
Lower risk of bleeding complications compared to unfractionated heparin
Mechanism of Action of Enoxawel 40
Enoxaparin selectively inhibits Factor Xa, preventing thrombus formation and reducing clot-related complications.